23 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Inhibiting NF-¿B-inducing kinase (NIK): discovery, structure-based design, synthesis, structure-activity relationship, and co-crystal structures.
Amgen
NF-kappaB inducing kinase (NIK) inhibitors: identification of new scaffolds using virtual screening.
University of Namur
An Alkynylpyrimidine-Based Covalent Inhibitor That Targets a Unique Cysteine in NF-?B-Inducing Kinase.
Newcastle University Centre For Cancer
Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor.
University of Arkansas For Medical Sciences
Pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of RET: Design, synthesis and biological evaluation.
University of Arkansas For Medical Sciences
The discovery of quinoline derivatives, as NF-?B inducing kinase (NIK) inhibitors with anti-inflammatory effects in vitro, low toxicities against T cell growth.
China Pharmaceutical University
Discovery of a Potent and Selective NF-?B-Inducing Kinase (NIK) Inhibitor That Has Anti-inflammatory Effects in Vitro and in Vivo.
Chinese Academy of Sciences
Structure-based rational design of staurosporine-based fluorescent probe with broad-ranging kinase affinity for kinase panel application.
Takeda Pharmaceutical
Structure Based Design of Potent Selective Inhibitors of Protein Kinase D1 (PKD1).
Genentech
A highly potent CDK4/6 inhibitor was rationally designed to overcome blood brain barrier in gliobastoma therapy.
Beijing Normal University
ROCK inhibitors 3: Design, synthesis and structure-activity relationships of 7-azaindole-based Rho kinase (ROCK) inhibitors.
Vertex Pharmaceuticals
ROCK inhibitors 2. Improving potency, selectivity and solubility through the application of rationally designed solubilizing groups.
Vertex Pharmaceuticals
Scaffold-Hopping Approach To Discover Potent, Selective, and Efficacious Inhibitors of NF-?B Inducing Kinase.
Genentech
New Substituted Cyanoindoline Derivatives as MAP3K14 Kinase Inhibitors for the Treatment of Cancer and Autoimmune Disorders.
Amri